Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside

L. Letendre, R. D. Niedringhaus, Terry M Therneau, D. A. Gastineau, R. M. Goldberg, J. B. Gerstner, J. A. Maillard, W. J. Gundlach, C. G. Kardinal, R. V. Pierre

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Effective treatment of the elderly patients (≥ 65 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (ARA-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] 1-hour infusion q12 hours for 12 doses) to 30 newly diagnosed and previously untreated patients. Complete remission was achieved in seven patients after the initial cycle of treatment, in two patients after retreatment, and in one patient after delayed recovery of his peripheral count over a 6-month period. The toxicity of this schedule was primarily hematologic, and the response rate was in keeping with that reported by other groups using aggressive multiagent regimens.

Original languageEnglish (US)
Pages (from-to)79-82
Number of pages4
JournalMedical and Pediatric Oncology
Volume17
Issue number2
StatePublished - 1989

Fingerprint

Cytarabine
Acute Myeloid Leukemia
Therapeutics
Retreatment
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Letendre, L., Niedringhaus, R. D., Therneau, T. M., Gastineau, D. A., Goldberg, R. M., Gerstner, J. B., ... Pierre, R. V. (1989). Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside. Medical and Pediatric Oncology, 17(2), 79-82.

Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside. / Letendre, L.; Niedringhaus, R. D.; Therneau, Terry M; Gastineau, D. A.; Goldberg, R. M.; Gerstner, J. B.; Maillard, J. A.; Gundlach, W. J.; Kardinal, C. G.; Pierre, R. V.

In: Medical and Pediatric Oncology, Vol. 17, No. 2, 1989, p. 79-82.

Research output: Contribution to journalArticle

Letendre, L, Niedringhaus, RD, Therneau, TM, Gastineau, DA, Goldberg, RM, Gerstner, JB, Maillard, JA, Gundlach, WJ, Kardinal, CG & Pierre, RV 1989, 'Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside', Medical and Pediatric Oncology, vol. 17, no. 2, pp. 79-82.
Letendre, L. ; Niedringhaus, R. D. ; Therneau, Terry M ; Gastineau, D. A. ; Goldberg, R. M. ; Gerstner, J. B. ; Maillard, J. A. ; Gundlach, W. J. ; Kardinal, C. G. ; Pierre, R. V. / Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside. In: Medical and Pediatric Oncology. 1989 ; Vol. 17, No. 2. pp. 79-82.
@article{5cf6162cd2c746818ceabda86755261c,
title = "Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside",
abstract = "Effective treatment of the elderly patients (≥ 65 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (ARA-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] 1-hour infusion q12 hours for 12 doses) to 30 newly diagnosed and previously untreated patients. Complete remission was achieved in seven patients after the initial cycle of treatment, in two patients after retreatment, and in one patient after delayed recovery of his peripheral count over a 6-month period. The toxicity of this schedule was primarily hematologic, and the response rate was in keeping with that reported by other groups using aggressive multiagent regimens.",
author = "L. Letendre and Niedringhaus, {R. D.} and Therneau, {Terry M} and Gastineau, {D. A.} and Goldberg, {R. M.} and Gerstner, {J. B.} and Maillard, {J. A.} and Gundlach, {W. J.} and Kardinal, {C. G.} and Pierre, {R. V.}",
year = "1989",
language = "English (US)",
volume = "17",
pages = "79--82",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside

AU - Letendre, L.

AU - Niedringhaus, R. D.

AU - Therneau, Terry M

AU - Gastineau, D. A.

AU - Goldberg, R. M.

AU - Gerstner, J. B.

AU - Maillard, J. A.

AU - Gundlach, W. J.

AU - Kardinal, C. G.

AU - Pierre, R. V.

PY - 1989

Y1 - 1989

N2 - Effective treatment of the elderly patients (≥ 65 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (ARA-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] 1-hour infusion q12 hours for 12 doses) to 30 newly diagnosed and previously untreated patients. Complete remission was achieved in seven patients after the initial cycle of treatment, in two patients after retreatment, and in one patient after delayed recovery of his peripheral count over a 6-month period. The toxicity of this schedule was primarily hematologic, and the response rate was in keeping with that reported by other groups using aggressive multiagent regimens.

AB - Effective treatment of the elderly patients (≥ 65 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (ARA-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] 1-hour infusion q12 hours for 12 doses) to 30 newly diagnosed and previously untreated patients. Complete remission was achieved in seven patients after the initial cycle of treatment, in two patients after retreatment, and in one patient after delayed recovery of his peripheral count over a 6-month period. The toxicity of this schedule was primarily hematologic, and the response rate was in keeping with that reported by other groups using aggressive multiagent regimens.

UR - http://www.scopus.com/inward/record.url?scp=0024544608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024544608&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 79

EP - 82

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -